Personalized Medicine In The Treatment Of Cardiovascular Disease.: Original Article

Kamran Riaz; Zia ul Hassan; Rafi ullah; Zakir Ullah; Muhammad Ejaz

doi:10.64911/qs4rbc66

Authors

Kamran Riaz Trainee Medical Officer HMC Peshawar Author https://orcid.org/0009-0003-1187-6382
Zia ul Hassan Trainee Medical Officer Jinnah Medical College, Peshawar Author https://orcid.org/0000-0002-6489-5603
Rafi ullah FCPS Cardiology, Fellow Interventional Cardiology HMC Peshawar Author
Zakir Ullah FCPS Cardiology, Fellow Interventional Cardiology HMC Peshawar Author https://orcid.org/0009-0005-6709-0367
Muhammad Ejaz FCPS Cardiology, Fellow Intervention Cardiology HMC Peshawar Author https://orcid.org/0009-0004-7707-9885

DOI:

https://doi.org/10.64911/qs4rbc66

Keywords:

Cardiovascular Diseases,Pharmacogenomics,Quality of Life

Abstract

Background: focuses on genetic characteristics and patient-specific environmental and behavioral patterns to devise treatment plans. This approach aims to maximize treatment outcomes, minimize side effects, and enhance the prediction of treatment outcomes.

Objectives: to evaluate the role of personalization of treatment in cardiology on the integration of genetic disposition and pharmacological therapies, and the impact on lifestyle modification in improving outcomes and reducing complication risks during the treatment.

Methodology: A total of 200 patients are undergoing diagnostic evaluation for cardiovascular conditions. The mean age of participants was 56.4 ± 11.8 years. Baseline data were collected on clinical presentation, molecular parameters, and pharmacological therapy response, along with assessments of lifestyle and health behaviors. Treatment decisions were guided by advanced imaging, biomarker evaluation, and integrated risk prediction algorithms. Patient outcomes were monitored over a 12-month follow-up period.

Results: 200 patients whose Mean age was 56.4 ± 11.8 years. Individualized medical therapies provided patients with specific health benefits by decreasing the adverse responses to medications. Patients who received personalized medication reported a 20% reduction in treatment-related heart complications compared to patients who received standard therapeutic care. Pharmacogenomic approaches empowered specialists to escalate drug regimens, which resulted in 15% reductions in adverse effects. Robust diagnostic tools and genetic tests, combined, provided physicians with precise treatment and care options, which enabled personalized approaches to medicine to statistically outperform the standard care model at p = 0.03. The data indicate that specific modifications to the management of progressive cardiovascular disease improve the efficiency of the designed strategies.

Conclusion: Cardiovascular medicine prioritizes effective, patient-centered methods to minimize adverse consequences and improve quality of life.